Results 51 to 60 of about 7,521 (213)

Hepatitis B Virus RNA Predicts Hepatocellular Carcinoma Despite Viral Suppression

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 8, Page 1089-1098, April 2026.
Serum HBV RNA levels at viral suppression predict HCC development in nucleos(t)ide analogue‐treated patients with chronic hepatitis B, outperforming Hepatitis B core‐related antigen alone. ABSTRACT Background Despite achieving undetectable hepatitis B virus (HBV) DNA levels with nucleos(t)ide analogue (NA) therapy, patients with chronic hepatitis B ...
Takashi Kumada, Hidenori Toyoda, Satoshi Yasuda, Yuichi Koshiyama, Takanori Ito, Tomoyuki Akita, Junko Tanaka   +6 more
wiley   +1 more source

Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B [PDF]

, 2003
BACKGROUND In preclinical and phase 2 studies, adefovir dipivoxil demonstrated potent activity against hepatitis B virus (HBV), including lamivudine-resistant strains.
Brosgart, Carol L., , M.D., Chang, Ting-Tsung, , M.D., Fry, John, , B.Sc., Goodman, Zachary, , M.D., Ph.D., Jeffers, Lennox, , M.D., Lim, Seng Gee, , M.D., Marcellin, Patrick, , M.D., Seivert, William, , M.D., Shiffman, Mitchell L., , M.D., Tong, Myron J., , Ph.D., M.D., Wulfsohn, Michael S., , M.D., Ph.D., Xiong, Shelly, , Ph.D.   +11 more
core   +2 more sources

HBeAg and Anti HBe Status in Patients with Chronic Hepatitis B Infection [PDF]

, 2010
Background: Data on HBeAg and anti HBe status in patients with chronic hepatitis B infection are not yet available in Indonesia. This study was done to acquire data on HBeAg and anti HBe status in patients with hepatitis B chronic infection. Method: The
Achwan, W. A. (Wenny), Gunawan, S. (Stephanus), Laksono, B. T. (Baskoro), Mahendra, K. (Ketut), Soemohardjo, S. (Soewignjo), Taufiq, H. S. (Herman), Widita, H. (Haris), Wilusanta, I. G. (I)   +7 more
core   +1 more source

Prevalence and Risk Factors of Elevated Alanine Aminotransferase (ALT) in 2382 Treatment‐naïve HBV/HDV Co‐Infected Patients

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT Background Chronic hepatitis D (CHD) causes severe chronic hepatitis. Knowledge is limited about factors correlating with ALT in treatment‐naïve patients with CHD. This study analysed the pattern and determinants of ALT elevation in a large cohort of patients with CHD, including young adults, compared to propensity score‐matched (PSM) patients
Habiba Kamal, Ganbolor Jargalsaikhan, Sanjaasuren Enkhtaivan, Karin Lindahl, Hannes Hagström, Daniel Bruce, Michael Ingre, Bekhbold Dashtserenx, Oyungerel Lkhagva‐Ochir, Tuvshinjargal Ulziibadrakh, Andreas Bungert, Heiner Wedemeyer, Naranjargal B. Dashdorj, Soo Aleman   +13 more
wiley   +1 more source

Clinical trial of lamivudine in children with chronic hepatitis B. [PDF]

, 2002
N Engl J Med. 2002 May 30;346(22):1706-13. Clinical trial of lamivudine in children with chronic hepatitis B. Jonas MM, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, Greensmith MJ, Gardner SD, Bell MS, Sokal EM; International Pediatric ...
Areias, J.A., Badia, I.B., Bell, M.S., Gardner, S.D., Greensmith, M.J., International Pediatric Lamivudine Investigator Group., Jonas, M.M., Little, N.R., Mizerski, J., Schwarz, K.B., Sokal, E.M.   +10 more
core   +1 more source

Vaccines at the Heart of Hepatitis Elimination: Insights From the ESCMID Study Group for Viral Hepatitis (ESGVH)

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT The global elimination of viral hepatitis by 2030 remains an ambitious goal that hinges not only on diagnostics and therapeutics but fundamentally on the strategic use and continued innovation of vaccines. The ESCMID Study Group for Viral Hepatitis (ESGVH) convened to examine the role of vaccination as the cornerstone of hepatitis prevention ...
Oana Săndulescu, Gülşen Özkaya Şahin, Susanne Gjeruldsen Dudman, Zeinab Nabil Ahmed Said, Mario U. Mondelli, on behalf of ESCMID Study Group for Viral Hepatitis (ESGVH)   +5 more
wiley   +1 more source

A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice

International Journal of Infectious Diseases, 2017
Aim: This study developed and validated a non-invasive scoring model to predict 1-year hepatitis B e antigen (HBeAg) seroconversion in response to nucleos(t)ide analog (NA) treatment in NA-naïve patients with HBeAg-positive chronic hepatitis B (CHB ...
Mingfan Geng, Yuxin Li, Fangyuan Gao, Le Sun, Xue Yang, Rui Wang, Jialiang Chen, Qun Zhang, Gang Wan, Xianbo Wang   +9 more
doaj   +1 more source

The Serumal Concentration of Hbsag in Patiets with Chb/hiv Co-infection Comparing with Chb Mono-infection in the Different Phases of Natural Course of Chronic Hepatitis В [PDF]

, 2016
The prevalence and inclination to chronization of viral hepatitis B is 3 – 5 times higher in patients with HIV-infection than in HIV-negative ones. The natural clinical course of chronic hepatitis B (CHB) in patients with HIV has the features, connected ...
Melnyk, T. (Tetiana), Moroz, L. (Larisa)
core  

Serum Interleukin-37 Concentrations and HBeAg Seroconversion in Chronic HBV Patients During Telbivudine Treatment [PDF]

Journal of Interferon & Cytokine Research, 2013
IL-37 is a new anti-inflammatory cytokine that plays an important role in protecting against tissue injury during infections via limiting immune and inflammatory reactions. This study aimed at determining serum IL-37 concentrations and HBeAg seroconversion in chronic hepatitis B virus (HBV) patients during Telbivudine (LDT) treatment.
Cong, Li, Huifan, Ji, Yanjun, Cai, Desalegn Admassu, Ayana, Pin, Lv, Maosheng, Liu, Yanfang, Jiang   +6 more
openaire   +2 more sources

Impact of Metabolic Associated Steatotic Liver Disease on Antiviral Therapy Outcomes on Chronic Hepatitis B Patients Receiving Antiviral Therapy

Journal of Medical Virology, Volume 98, Issue 3, March 2026.
ABSTRACT Background and Aim Chronic hepatitis B (CHB) affects over 250 million people globally and is a major contributor to liver complications, including cirrhosis and hepatocellular carcinoma (HCC). Though antiviral therapies suppress HBV, the rising prevalence of metabolic‐associated steatotic liver disease (MASLD) poses new challenges.
Sheng‐Jie Shiue, Tung‐Han Ho, Hsin‐Yi Lin, Sheng‐Wei Cheng, Li‐Wei Wu, Tze‐Sian Chan, Chun‐Nan Chen, Chao‐Ling Cheng, Yan Kang Lee, Hsien‐Yao Yang, Han‐Shiang Shiue, Kuo‐Feng Leng, Ming‐Shun Wu   +12 more
wiley   +1 more source